Evidence map›Paper›PMID 28870518›Full record

ArticleNeurobiology of aging2017

MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.

Hayk Davtyan, Karen Zagorski, Irina Petrushina, Konstantin Kazarian, Natalie R S Goldberg, Janet Petrosyan, Mathew Blurton-Jones, Eliezer Masliah, David H Cribbs, Michael G Agadjanyan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hayk DavtyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Karen ZagorskiDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA.
Irina PetrushinaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Konstantin KazarianDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA.
Natalie R S GoldbergInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Janet PetrosyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA.
Mathew Blurton-JonesInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Eliezer MasliahDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA; Department of Pathology, University of California, San Diego, La Jolla, CA, USA.
David H CribbsInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Michael G AgadjanyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. Electronic address: magadjanyan@immed.org.
Anahit GhochikyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA. Electronic address: aghochikyan@immed.org.
University of California, Irvine · USInstitute for Molecular Medicine · USUniversity of California San Diego · US

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
Combining AD Epitope Vaccine with Innate ImmunityR01NS050895 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2004 to 2018
$7.4M
Multiple Approaches to Abeta Vaccination in Animal ModelsR01AG020241 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2001 to 2016
$5.6M
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 INDU01AG048310 · NIA · INSTITUTE FOR MOLECULAR MEDICINE · PI AGADJANYAN, MICHAEL G · 2015 to 2018
$4.5M
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
Multiple Approaches to Abeta Vaccination in Animal ModelsRF1AG020241 · NIA · INSTITUTE FOR MOLECULAR MEDICINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2018 to 2018
$3.3M
NIA NIH HHS P50 AG016573NIA NIH HHS R01 AG020241NIA NIH HHS RF1 AG020241NIA NIH HHS U01 AG048310NINDS NIH HHS R01 NS050895
6 · The paper itself

Abstract

We have previously demonstrated that anti-beta amyloid DNA vaccine (AV-1959D) based on our proprietary MultiTEP platform technology is extremely immunogenic in mice, rabbits, and monkeys. Importantly, MultiTEP platform enables development of vaccines targeting pathological molecules involved in various neurodegenerative disorders. Taking advantage of the universality of MultiTEP platform, we developed DNA vaccines targeting 3 B-cell epitopes (amino acids [aa]85-99, aa109-126, and aa126-140) of human alpha-synuclein (hα-Syn) separately or all 3 epitopes simultaneously. All 4 DNA vaccines (1) generate high titers of anti-hα-Syn antibodies and (2) induce robust MultiTEP-specific T-helper cell responses without activation of potentially detrimental autoreactive anti-hα-Syn T-helper cells. Generated antibodies recognize misfolded hα-Syn produced by neuroblastoma cells, hα-Syn in the brain tissues of transgenic mouse strains and in the brain tissues of dementia with Lewy body cases. Based on these results, the most promising vaccine targeting 3 B-cell epitopes of hα-Syn simultaneously (PV-1950D) has been chosen for ongoing preclinical assessment in mouse models of hα-Syn with the aim to translate it to the human clinical trials.

Indexed as

alpha-SynucleinAnimalsAntibodiesEpitopes, B-LymphocyteFemaleHumansMice, Inbred C57BLMice, TransgenicNeurodegenerative DiseasesT-Lymphocytes, Helper-InducerVaccines, DNAalpha-SynucleinAntibodiesEpitopes, B-LymphocyteVaccines, DNAAnti-α-synuclein antibodiesB-cell mappingDNA vaccinesImmunogenicityMultiTEP platformT-cell mappingTherapeutic potency

Identifiers

PMID28870518
PMCPMC5612893
OpenAlexW2745013286

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.